vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

Real Brokerage Inc is the larger business by last-quarter revenue ($568.5M vs $487.7M, roughly 1.2× CLOVER HEALTH INVESTMENTS, CORP.). Real Brokerage Inc runs the higher net margin — -0.1% vs -10.1%, a 10.0% gap on every dollar of revenue. On growth, Real Brokerage Inc posted the faster year-over-year revenue change (52.6% vs 44.7%). Real Brokerage Inc produced more free cash flow last quarter ($8.4M vs $-69.0M).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

CLOV vs REAX — Head-to-Head

Bigger by revenue
REAX
REAX
1.2× larger
REAX
$568.5M
$487.7M
CLOV
Growing faster (revenue YoY)
REAX
REAX
+7.9% gap
REAX
52.6%
44.7%
CLOV
Higher net margin
REAX
REAX
10.0% more per $
REAX
-0.1%
-10.1%
CLOV
More free cash flow
REAX
REAX
$77.4M more FCF
REAX
$8.4M
$-69.0M
CLOV

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CLOV
CLOV
REAX
REAX
Revenue
$487.7M
$568.5M
Net Profit
$-49.3M
$-447.0K
Gross Margin
7.9%
Operating Margin
-10.1%
-0.1%
Net Margin
-10.1%
-0.1%
Revenue YoY
44.7%
52.6%
Net Profit YoY
-123.2%
82.7%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
REAX
REAX
Q4 25
$487.7M
Q3 25
$496.6M
$568.5M
Q2 25
$477.6M
$540.7M
Q1 25
$462.3M
$354.0M
Q4 24
$337.0M
Q3 24
$331.0M
$372.5M
Q2 24
$356.3M
Q1 24
$346.9M
$200.7M
Net Profit
CLOV
CLOV
REAX
REAX
Q4 25
$-49.3M
Q3 25
$-24.4M
$-447.0K
Q2 25
$-10.6M
$1.5M
Q1 25
$-1.3M
$-5.0M
Q4 24
$-22.1M
Q3 24
$-9.2M
$-2.6M
Q2 24
$7.4M
Q1 24
$-19.2M
$-16.1M
Gross Margin
CLOV
CLOV
REAX
REAX
Q4 25
Q3 25
7.9%
Q2 25
8.9%
Q1 25
9.6%
Q4 24
Q3 24
24.5%
8.6%
Q2 24
30.3%
Q1 24
23.6%
10.3%
Operating Margin
CLOV
CLOV
REAX
REAX
Q4 25
-10.1%
Q3 25
-4.9%
-0.1%
Q2 25
-2.2%
0.3%
Q1 25
-0.3%
-1.5%
Q4 24
-6.4%
Q3 24
-2.7%
-0.7%
Q2 24
2.0%
Q1 24
-6.5%
-7.8%
Net Margin
CLOV
CLOV
REAX
REAX
Q4 25
-10.1%
Q3 25
-4.9%
-0.1%
Q2 25
-2.2%
0.3%
Q1 25
-0.3%
-1.4%
Q4 24
-6.6%
Q3 24
-2.8%
-0.7%
Q2 24
2.1%
Q1 24
-5.5%
-8.0%
EPS (diluted)
CLOV
CLOV
REAX
REAX
Q4 25
Q3 25
$0.00
Q2 25
$0.01
Q1 25
$-0.02
Q4 24
Q3 24
$-0.01
Q2 24
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$78.3M
$38.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$53.6M
Total Assets
$541.0M
$145.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
REAX
REAX
Q4 25
$78.3M
Q3 25
$38.7M
Q2 25
$49.7M
Q1 25
$24.7M
Q4 24
$194.5M
Q3 24
$288.0M
$22.6M
Q2 24
$254.8M
Q1 24
$208.3M
$20.1M
Stockholders' Equity
CLOV
CLOV
REAX
REAX
Q4 25
$308.7M
Q3 25
$340.9M
$53.6M
Q2 25
$344.2M
$49.2M
Q1 25
$336.1M
$32.8M
Q4 24
$341.1M
Q3 24
$342.2M
$29.8M
Q2 24
$324.9M
Q1 24
$292.5M
$25.6M
Total Assets
CLOV
CLOV
REAX
REAX
Q4 25
$541.0M
Q3 25
$559.7M
$145.2M
Q2 25
$575.0M
$149.4M
Q1 25
$583.7M
$100.5M
Q4 24
$580.7M
Q3 24
$653.0M
$102.5M
Q2 24
$674.2M
Q1 24
$671.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
REAX
REAX
Operating Cash FlowLast quarter
$-66.9M
$8.8M
Free Cash FlowOCF − Capex
$-69.0M
$8.4M
FCF MarginFCF / Revenue
-14.1%
1.5%
Capex IntensityCapex / Revenue
0.4%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
REAX
REAX
Q4 25
$-66.9M
Q3 25
$12.1M
$8.8M
Q2 25
$5.4M
$41.0M
Q1 25
$-16.3M
$15.9M
Q4 24
$34.8M
Q3 24
$50.0M
$7.2M
Q2 24
$44.8M
Q1 24
$25.9M
$21.5M
Free Cash Flow
CLOV
CLOV
REAX
REAX
Q4 25
$-69.0M
Q3 25
$11.4M
$8.4M
Q2 25
$4.8M
$40.8M
Q1 25
$-16.5M
$15.7M
Q4 24
$33.3M
Q3 24
$49.6M
$6.8M
Q2 24
$44.4M
Q1 24
$25.5M
$21.4M
FCF Margin
CLOV
CLOV
REAX
REAX
Q4 25
-14.1%
Q3 25
2.3%
1.5%
Q2 25
1.0%
7.5%
Q1 25
-3.6%
4.4%
Q4 24
9.9%
Q3 24
15.0%
1.8%
Q2 24
12.5%
Q1 24
7.3%
10.7%
Capex Intensity
CLOV
CLOV
REAX
REAX
Q4 25
0.4%
Q3 25
0.1%
0.1%
Q2 25
0.1%
0.0%
Q1 25
0.0%
0.1%
Q4 24
0.5%
Q3 24
0.1%
0.1%
Q2 24
0.1%
Q1 24
0.1%
0.0%
Cash Conversion
CLOV
CLOV
REAX
REAX
Q4 25
Q3 25
Q2 25
27.13×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons